Stifel on MacroGenics (MGNX): 'incrementally more positive', 'We remain buyers into the next “by May 31” clinical update'
Tweet Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $29.00 price target on MacroGenics (NASDAQ: MGNX).The analyst comments "We’re incrementally ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
